Department of Biomedical Sciences and.
Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
J Clin Invest. 2019 Oct 1;129(10):4050-4057. doi: 10.1172/JCI129194.
The metabolic syndrome (MetS) is a constellation of risk factors that, if left untreated, will often progress to greater metabolic defects such as type 2 diabetes and nonalcoholic fatty liver disease. While these risk factors have been established for over 40 years, the definition of MetS warrants reconsideration in light of the substantial data that have emerged from studies of the gut microbiome. In this Review we present the existing recent literature that supports the gut microbiome's potential influence on the various risk factors of MetS. The interplay of the intestinal microbiota with host metabolism has been shown to be mediated by a myriad of factors, including a defective gut barrier, bile acid metabolism, antibiotic use, and the pleiotropic effects of microbially produced metabolites. These data show that events that start in the gut, often in response to external cues such as diet and circadian disruption, have far-reaching effects beyond the gut.
代谢综合征(MetS)是一组危险因素,如果不加以治疗,通常会进展为更大的代谢缺陷,如 2 型糖尿病和非酒精性脂肪肝疾病。虽然这些危险因素已经存在了 40 多年,但鉴于肠道微生物组研究中出现的大量数据,MetS 的定义值得重新考虑。在这篇综述中,我们介绍了支持肠道微生物组对 MetS 各种危险因素潜在影响的现有最新文献。肠道微生物群与宿主代谢的相互作用已被证明是由多种因素介导的,包括肠道屏障缺陷、胆汁酸代谢、抗生素使用以及微生物产生的代谢物的多效性效应。这些数据表明,从肠道开始的事件,通常是对饮食和昼夜节律紊乱等外部线索的反应,其影响远远超出肠道。